Quantcast

Reportlinker Adds FoodService Disposables Report

September 8, 2009

NEW YORK, Sept. 8 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue.

FoodService Disposables

http://www.reportlinker.com/p0131234/FoodService-Disposables.html

This report analyzes the US market for FoodService Disposables in Millions of US$ by the following Product Types: Cups and Lids, Containers, Dinnerware, Napkins, and Others. This report also analyzes the US Market for Foodservice Disposables by End-Use Segments: Restaurants, Retail Stores, Institutions, and Others. Annual forecasts are provided for the period of 2006 through 2015. The report profiles 133 companies including many key and niche players such as Ace-Tex Plastic Sdn Bhd, Airlite Plastics Co., Alcan Inc., Ball Corporation, Berry Plastics Catering Products, C&M Fine Pack, Inc., Cascades Inc., Chuo Kagaku Co., Ltd., Dart Container Corp., Dopaco, Inc., Douglas Stephen Plastics, Inc., Duni Ab, Fabri-Kal Corp., Georgia-Pacific Corp., Huhtamaki Oyj, Inline Plastics Corp., Jim Pattison Group, Letica Corporation, M/S. Plus Paper Foodpac Limited, Mcnairn Packaging, Meadwestvaco Corporation, Menasha Corporation, Novelis Inc., Packaging Dynamics Corp., Pactiv Corporation, Rock-Tenn Co., Solo Cup Company, Southern Champion Tray, Lp, Svenska Cellulosa Aktiebolaget, v, Union Packaging, Llc, Waddington North America Inc., and Wincup, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level I-2

Quantitative Techniques & Analytics I-3

Product Definition and Scope of Study I-3

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW & OUTLOOK II-1

Pharma Industry Hit by Economic Downturn II-1

Table 1: Worldwide Prescription Drugs Sales: 2006-2015

(includes corresponding Graph/Chart) II-1

The Regional Impact II-1

Emerging Markets to Drive Growth II-2

Biotechnology II-2

Biotech Bankruptcies Rife in the Current Economic Downturn II-3

Economic Downturn Takes Toll on R&D II-3

Outsourcing – A Mixed Bag II-4

Generics – The Bright Spot II-6

Table 2: Increasing Share of Generics in the Global

Pharmaceutical Market: 1995-2005 (In %) (includes

corresponding Graph/Chart) II-6

Table 3: Generics Share in Select Markets Worldwide – United

States, Germany, UK, Spain, Japan, Italy, France, Finland,

Denmark, The Netherlands, Norway, and Ireland (includes

corresponding Graph/Chart) II-7

Patent Expiries of Major Drugs: 2009-2012 II-8

Patient Spending II-8

Operational Restructuring II-9

Rising R&D Costs Call for Improved Efficiency II-9

Concerns Over Drug Safety and Side Effects Impede Sales II-9

Policy Issues Threaten Innovation II-10

Regulatory Glitches and High Costs Hinder Biogeneric Growth II-10

Opportunities Outside Drug Development II-11

Going Forward in Forward Integration II-11

Forward Integration into Diagnostics II-11

Opportunities in Healthcare II-11

Down the Distribution Chain II-12

2. LEADING PHARMA COMPANIES AND DRUGS WORLDWIDE II-13

Pfizer Reigns Supreme II-13

Table 4: Leading Global Pharmaceutical Companies Worldwide by

Sales (2008, 2007, and 2006) – Pfizer, GlaxoSmithKline,

Novartis, Sanofi-Aventis, AstraZeneca, Roche, Johnson &

Johnson, Merck & Co., Abbott and Eli Lilly – in US$ Billion

(includes corresponding Graph/Chart) II-13

Leading Prescription Drugs Worldwide – Lipitor Leads the Way II-14

Table 5: Leading Prescription Drugs Worldwide by Sales (2008,

2007, and 2006)- Lipitor, Plavix, Nexium, Seretide, Enbrel,

Seroquel, Zyprexa, Remicade, Singulair and Levonox in US$

Billion (includes corresponding Graph/Chart) II-14

Oncology Tops Therapeutic Classes II-14

Table 6: Leading Therapeutic Classes Worldwide by Sales

(2008, 2007, and 2006)- Oncologics, Lipid Regulators,

Respiratory Agents, Proton Pump Inhibitors, Antidiabetics,

Antipsychotics, Antidepressants, Angiotensin II Antagonists,

Anti-Epileptics, Autoimmune Agents and Others in US$ Billion

(includes corresponding Graph/Chart) II-15

3. THERAPEUTIC DRUG CLASSES II-16

Cholesterol Reducers II-16

Statins Lead the Way II-16

Emerging Leaders II-16

Table 7: Leading Cholesterol Reducing Drugs Worldwide: Sales

for the years 2004 through 2008 for Lipitor, Crestor and

Vytorin (in US$ Billion) (includes corresponding

Graph/Chart) II-16

Lack of Product Differentiation Mars ProspectsII-17

Zocor – The First Statin to Switch to OTC II-17

Patent Expiries of Leading Cholesterol Reducers: 2009 and

Beyond II-17

Oncologics II-17

Oncologics/ Cancer Drugs – Largest Therapeutic Class II-17

High Unmet Needs to Drive Growth II-17

Biologics to Reign Supreme II-18

Leading Drugs II-18

Leading Players II-18

Novel Therapies II-18

Respiratory Drugs II-19

Leading Brands and Players II-19

Table 8: Leading Asthma Drugs Worldwide – Value Sales for

the Years 2004-2008 for Seretide, Singulair, Symbicort and

Pulmicort (in US$ Billion) (includes corresponding

Graph/Chart) II-19

Table 9: Select COPD and Allergic Rhinitis Drugs Worldwide:

Value Sales for the Years 2006-2008 for Spiriva, Nasonex

and Zyrtec (In US$ Billion) (includes corresponding

Graph/Chart) II-20

Patent Expiries of Leading Respiratory Drugs: 2008 and Beyond II-20

Antipsychotics II-20

Leading Schizophrenia Drugs II-21

Side Effects of Antipsychotics – A Major IssueII-21

Patent Expiries II-21

Patent Expiries of Leading Anti-Psychotic Drugs II-22

Zyprexa Continues to Lose Market Share II-22

Risperdal Sales to Plunge, Following its Patent Expiry II-22

Generics – Yet to Make a Mark in Antipsychotics II-22

Increasing Use of Antipsychotics in Children Raises Concerns II-22

Proton Pump Inhibitors II-23

Patent Expiries of Leading Proton Pump Inhibitors: 2008 and

Beyond II-24

Table 10: Leading Proton Pump Inhibitors Worldwide – Value

Sales for the Years 2004 through 2006 (US$ Billion) – Nexium,

Prevacid/Takepron, Protronix/Pantazol and AcipHex/Pariet

(includes corresponding Graph/Chart) II-24

Antidepressants II-24

Patent Expiries of Leading Antidepressant Drugs Worldwide:

2005-2015 II-25

Erythropoietins II-25

Competitive Landscape in the Global Erythropoietin Market II-26

Leading Erythropoietin Drugs II-26

Table 11: Leading Erythropoietin Drugs Worldwide – Annual

Revenues for the Years 2004 through 2007 in US$ Billion for

Aranesp, Procrit/Eprex, Epogen and NeoRecormon (includes

corresponding Graph/Chart) II-26

New and Pipeline Products II-27

Biogenerics Pose Imminent Threat II-27

Anti-Arthritics II-27

Table 12: Leading Anti-arthritic Drugs Worldwide – Value

Sales for Years 2006 through 2008 in US$ Billion – Enbrel,

Remicade, Rituxan and Humira (includes corresponding

Graph/Chart) II-28

Anti-Epileptics II-28

Disease Statistics II-29

Available Drugs II-29

Generics to Take the Lead in Anti-Epileptic Market II-29

Table 13: Leading Anti-Epileptic Drugs Worldwide: Value

Sales for years 2005 through 2007 in US$ Billion for

Topamax, Lamictal, Depakote and Keppra (includes

corresponding Graph/Chart) II-30

Patent Expiries of Leading Anti-Epileptic Drugs II-30

New Launches II-30

Pipeline Drugs Bode Brighter Prospects II-30

Pipeline Drugs in Antiepileptics II-31

Calcium Channel BlockersII-31

Antidiabetics II-31

Table 14: Leading Anti-diabetic Drug Sales Worldwide: Value

Sales for Years 2005 through 2008 in US$ Billion for Actos,

Lantus, Avandia Franchise, Januivia and Byetta (includes

corresponding Graph/Chart) II-32

4. MARKET DYNAMICS II-33

Pharma M&A Activity in 2008 II-33

Aggressive M&A Deals by Japanese Companies II-34

Patent Expiries II-34

Patent Expiries for 2008 and 2007 II-35

New Product Approvals II-35

Table 15: New Drugs Approval from 2003-2008 (includes

corresponding Graph/Chart) II-36

Table 16: Biologics Approvals from 2003-2008 (includes

corresponding Graph/Chart) II-36

Table 17: Development of New Molecular Entities (Biological

and Chemical) by Various Region/Country: Percentage Share

Breakdown for the Periods 1998-2002 & 2003-2007 (includes

corresponding Graph/Chart) II-37

Table 18: Number of Compounds Under Development by

Country/Region: Percentage Breakdown for the year 2007

(includes corresponding Graph/Chart) II-37

New Molecular Entities (NMEs) Approved by FDA in 2008 II-38

New Biological Entities Approved by FDA in 2008 II-38

Research and DevelopmentII-39

Table 19: R&D Investments by Pharmaceutical Sector in US and

Europe: 2004-2007 (includes corresponding Graph/Chart) II-39

Cost Pressures II-39

R&D Productivity Slides Despite Increasing Investments II-39

Aging Population Drives Demand II-40

Table 20: World Demographic Trends: People Over 65 as a

Percentage of Total Population by Geographic Region- US,

Canada, Japan, Europe, Asia-Pacific, and Latin America for

years 2000, 2008, 2010, and 2020 (includes corresponding

Graph/Chart) II-40

5. PRESCRIPTION PHARMACEUTICALS – AN OVERVIEW II-41

Biologics II-41

Evolution Of The Global Pharmaceutical IndustryII-42

Drug Development Process – FDA Perspective II-43

Stages of Drug Development Process II-43

Drug Discovery II-43

Pre-Clinical Testing II-43

Clinical Trials II-43

Phase I Clinical TrialII-44

Phase II Clinical Trial II-44

Phase III Clinical Trial II-44

New Drug Application II-44

FDA Review II-44

Phase IV Clinical Trials II-44

FDA’s Drug Safety Review – The Global Standard II-44

6. SELECT THERAPEUTIC CLASSES II-46

Anti-arthritics II-46

COX-2 Inhibitors II-46

Antipsychotic Drugs II-46

Anti-Ulcerants II-47

Codeine & Combinations II-47

Combination Drugs II-48

Anti-Depressants II-48

Selective Serotonin Reuptake Inhibitors (SSRIs) II-48

Serotonin Noradrenaline Re-Uptake Inhibitors (SNRIs) II-49

Serotonin Modulators (5-HT2 blockers) II-49

Dopamine-norepinephrine Reuptake Inhibitors II-49

Monoamine Oxidase Inhibitors (MAOIs) II-50

Erythropoietin II-50

Proton Pump Inhibitors II-50

Seizure Disorder Drugs II-51

Antihistamines II-52

Calcium Channel BlockersII-53

Cholesterol Reducers II-54

7. MARKETING AND PROMOTIONS II-55

Table 21: Promotional Spending by Major Pharma Companies (2006

and 2007) in US$ Million – Pfizer, GlaxoSmithKline, Merck,

AstraZeneca, Sanofi-Aventis, Novartis, Eli Lilly,

Schering-Plough, Johnson & Johnson, and Bristol Myers Squibb

(includes corresponding Graph/Chart) II-55

Table 22: Promotional Spending through Professional Detailing

by Major Pharma Companies (2006 and 2007) in US$ Million -

Pfizer, GlaxoSmithKline, Merck, AstraZeneca, Novartis,

Sanofi-Aventis, Eli Lilly, Johnson & Johnson, Schering-Plough

and Wyeth (includes corresponding Graph/Chart) II-56

Table 23: Direct-To-Consumer Promotional Spending By Major

Pharma Companies (2006 and 2007) in US$ Million – Pfizer,

GlaxoSmithKline, Merck, Bristol Myers Squibb, Sepracor,

AstraZeneca, Schering-Plough, Sanofi-Aventis, Boehringer

Ingelheim and Eli Lilly (includes corresponding Graph/Chart) II-56

Table 24: E-Promotional Spending by Major Pharma Companies

(2006 and 2007) in US$ Million – Merck, GlaxoSmithKline,

Johnson & Johnson, Pfizer, Shire, Eli Lilly, Schering-Plough,

AstraZeneca and Sanofi- Aventis (includes corresponding

Graph/Chart) II-57

8. RECENT INDUSTRY ACTIVITY II-58

Merck & Co. And Schering-Plough to Merge II-58

Pfizer to Acquire Wyeth II-58

CSL and Talecris Biotherapeutics to Withdraw Merger Agreement II-58

AstraZeneca Partners with Merck to Analyze a New Combination

of Anticancer Regimen II-58

Sun Pharmaceutical Acquires ChattemII-59

Novartis Acquires 25% Stake in Alcon II-59

Takeda Acquires Millenium Pharmaceuticals II-59

Teva Acquires Barr II-60

Invitrogen and Applied Biosystems Merge II-60

Eli Lilly Takes Over ImClone Systems II-60

Daiichi- Sankyo Acquires Controlling Stake in Ranbaxy II-60

Fresenius Acquires APP Pharmaceuticals II-61

TPG Acquires 50% Stake in SIA International II-61

GSK Acquires Sirtris II-61

Shire Acquires Controlling Interest in Jerini II-61

Boehringer Ingelheim to Purchase Actimis Pharmaceuticals II-61

Sanofi Pasteur Acquires Acambis II-62

Sanofi-Aventis Acquires Symbion II-62

Nordic and Avista Acquires ConvaTecII-62

King Pharmaceuticals Acquires Alpharma II-62

Shionogi Acquires ScieleII-63

Ranbaxy Inks Indian Marketing License for GLIADEL(R) with BioPro II-63

Tibotec Gains EC Approval for PREZISTA(R)’s Extended Indication II-63

GSK and Neptunus to Set up Joint Venture for Developing Flu

Vaccines II-64

AstraZeneca Obtains TRO for Generic Pulmicort Respules II-64

Solvay Pharmaceuticals Enters Into a License Deal with Depomed II-64

AstraZeneca Enters into an Agreement with Par Pharmaceutical II-65

BioReliance and Provecs Enter into Agreement II-65

Cornerstone BioPharma and Critical Therapeutics Merge to Form

Cornerstone Therapeutics II-65

GSK to Acquire Genelabs II-66

Lpath and Merck Serono Forge Partnership II-66

Allergan and Spectrum Ink Collaboration Deal for Bladder

Cancer Drug II-66

EMD Signs Licensing and Collaboration Deal with

Theratechnologies II-67

Medimetriks Receives License for Prescription Brands from

Perrigo II-67

Forest Partners with Phenomix for Developing Diabetic Drug II-68

GSK Biologicals and AFFiRiS Sign Collaboration Agreement II-68

Sanofi-Aventis Strengthens R&D Operations in the Chinese Market II-68

UCB and Pfizer Establish Cyclofluidic II-69

Valeant Pharmaceuticals Completes Coria Laboratories Acquisition II-69

MedImmune Inks Agreement with Omninvest over Reverse Genetic

Technology II-70

Avidas Secures North American Rights of Crown’s Dermatology

Products II-70

Lilly Acquires Two Compounds for Early-Stage Tuberculosis

Drug Pipeline II-71

Eli Lilly and Deciphera Enter into Collaboration and

Licensing Deal II-71

Roche, GlycArt and Genentech Sign Collaboration Agreement II-72

Cardinal Health Plans to Spin-Off Medical and Clinical

Products Businesses II-72

Sanofi Pasteur Holding Acquires Acambis II-72

Eisai Plans NDA Submission for Insomnia Drug II-73

GlaxoSmithKline Enter into Strategic Alliance with Cellzome II-73

Ablynx and Merck Serono Sign Nanobodies(R) Agreement II-74

GlaxoSmithKline and Valeant Enter into Collaborative Agreement II-74

Noven Enters Supply and License Agreements with P&G

Pharmaceuticals II-75

Eli Lilly Acquires SGX Pharmaceuticals II-75

SymBio Pharmaceuticals Enters into a License Agreement with

Eisai II-75

Roche Sells Four Pharmaceutical Products to Meda AB II-76

AstraZeneca Joins Hands with Abbott for Co-Promotion of Crestor II-76

Gilead Sciences Inks Atripla(R), HIV Drug Distribution Deal

with Merck II-77

Eisai China Enters into Licensing Deal with Health Vision II-77

GSK and Harvard Stem Cell Institute Team Up for Drug Discovery II-78

Teva Acquires Bentley Pharmaceuticals II-78

Roche to Acquire ARIUS Research II-78

GlaxoSmithKline and Actelion Collaborate II-79

GSK Enters into Product Disinvestment Agreement with Aspen II-79

Lupin Forges Marketing Alliance with ASCEND for Suprax(R) Tablets II-80

Merck Serono Inks Multiple Sclerosis Drug-Development Deal

with Bionomics II-80

European Commission Approves Kuvan(R) of Merck Serono II-81

GSK Collaborates with Mpex for Developing Anti-Bacterial Drugs II-81

Eli Lilly Announces Development & Licensing Agreement with

TransPharma II-81

Mylan Obtains Exclusive Marketing Rights for Glatiramer from

NATCO II-82

Sepracor Acquires Oryx Pharmaceuticals II-82

Mylan Takes Over Merck’s Outstanding Generics Operations II-83

Gilead Acquires Cicletanine Business from Navitas II-83

King Pharmaceuticals to License Third Opioid Analgesic Product II-84

BioPhausia Acquires Prescription Pharmaceutical Offerings

from AstraZeneca II-84

Ranbaxy Enters into Strategic Product Development Agreement

with Merck II-84

EUSA Pharma Acquires Cytogen Corporation II-85

Dr. Reddy’s Announces Two Major Acquisitions II-85

EUSA Divests Stake in Antibody Research and Oncology Product

to IDD II-85

Sanofi Pasteur Delivers H5N1 Bulk Vaccine Antigen to HHS II-86

Ranbaxy Inks Strategic Business Alliance with Orchid II-86

Pfizer Settles Patent Litigation for Lipitor with Ranbaxy II-87

GSK Enters into Collaboration with Regulus Therapeutics II-87

Janssen to Launch J&J Group’s New Drugs in Japan II-88

Roche Alliance Partner Obtains Approval for Actemra in Japan II-88

Abbott Receives Japanese Approval for Rheumatoid Arthritis

Drug, HUMIRA(R) II-88

Dr. Reddy’s Completes Acquisition of Jet Generici Srl II-89

Eli Lilly, Transition Therapeutics Announce Licensing and

Partnership Agreement II-89

Dr. Reddy’s and 7TM Sign Drug Discovery Agreement for

Selected Drug Targets II-89

Endo Pharmaceuticals Obtains US Rights for Novartis’

Voltaren(R) Gel II-90

Pfizer to Take Over Serenex II-90

Sanofi-aventis, Amyris, iOWH Sign Semisynthetic Artemisinin

Development Deal II-91

AstraZeneca Files sNDA for Depressive Disorder Drug, Seroquel

XR(TM) II-91

Forest, Mylan Amend Bystolic Agreement II-92

Fujifilm to Acquire Stake in Toyama Chemicals II-92

Graceway Takes Over Estrasorb II-92

Ranbaxy Announces De-Merger of New-Drug Discovery Research Unit II-93

AstraZeneca Inks Deal with Nomura Phase4 Ventures to Form

Albireo II-93

Cellegy to Merge with Adamis Pharmaceuticals II-93

Mylan Reaches Accord with Novartis for Femara(R)’s Generic Product II-93

Dyax Signs Licensing and Development Agreements with Sanofi-

aventis II-94

AstraZeneca Files for EU Approval of Seroquel XR(TM) II-94

MedImmune Files Biologics License Application for motavizumab

to FDA II-94

Farmavita, Belupo Sign Contract for Strategic Merger II-94

Pfizer Japan Secures Production and Marketing Approval for

Champix(R) II-95

Eisai Enters into License Agreement with AbbottII-95

Eisai Takes Over MGI Pharma II-96

KV Pharmaceutical to Acquire Rights for Gestiva(TM) from Hologic II-96

Forest and Novexel Enter into Licensing Agreement II-96

Dr. Reddy’s Enters Settlement Agreement with Novartis for

Exelon(R) II-97

Taisho and Pfizer Sign Agreement for TS-032 II-97

Crucell Enters into Agreement with Sanofi Pasteur II-97

EMEA Approves Second Biogeneric EPO, Retacrit II-98

Endo Pharmaceuticals Licenses AZ-003 from Alexza II-98

Schering-Plough and Centocor Modify Existing Distribution

Agreement II-98

GSK and Santaris Pharma Collaborate in RNA Antagonists Research II-99

GSK Acquires Reliant Pharmaceuticals II-99

Eisai and Minophagen Ink In-Licensing Agreement for Liver

Disease/ Allergic Disease Agents II-100

Bristol-Myers, Gilead Extend Agreement to Commercialize

ATRIPLA(R) in Europe II-100

GSK and OncoMed Team Up for Antibody Therapeutics for Cancer

Stem Cell Research II-101

GSK Allies with Galapagos for Antiviral and Antibacterial

Development II-101

Eisai and BioArctic Ink Licensing Deal for BAN2401 II-102

Biogen and Neurimmune Join Hands to Develop Drugs for

Alzheimer’s Disease II-102

Sanofi-aventis Institutes GDC, Pharmaceutical Development

Center in India II-103

AstraZeneca Obtains Pediatric Exclusivity for ARIMIDEX(R) from FDA II-103

Covance to Build High-Tech Drug Development Facility II-103

Schering-Plough Takes Over Organon BioSciences II-104

Takeda Launches Takeda San Francisco for Therapeutic Antibody

Research II-104

GSK to Disinvest Lotronex(R) II-104

Gilead and LGLS Enter Global License Deal for Fibrotic

Diseases Therapy II-105

Watson Acquires Andrx II-105

EPFL and Merck Serono Enter into Agreement II-106

Acura and King R&D Sign Licensing Agreement for Opioid

Analgesic Products II-106

Eli Lilly Inks License Agreement with Glenmark Pharmaceuticals II-107

Wockhardt Takes Over Morton Grove Pharmaceuticals II-107

GSK Enters into Collaboration with Tolerx for Development of

Novel Therapies II-108

Chugai Pharmaceuticals Obtains Approval for Tarceva in Japan II-108

Eli Lilly Announces Strategic Alliance with MacroGenics II-108

BMS, ImClone, Merck Serono Sign Erbitux(R) Agreement II-109

Wockhardt to Market Gnosis’ SAMe in India II-110

Alpharma Grants US License for Ketoprofen in Transfersome(R)

Gel to IDEA II-110

Forest and Daiichi Sankyo Sign Contract to Co-Promote AZOR(TM) II-110

Synta and GSK Sign Oncology Molecule Development Collaboration II-110

Cyclacel to Take Over ALIGN Pharmaceuticals and ALIGN Holdings II-111

GSK Inks Antiviral and Antibacterial Drug Development Deal

with Anacor II-111

AMRI Enters into Research Collaboration with Cystic Fibrosis

Foundation II-112

Mylan Takes over Merck Generics II-112

Kissei and Eisai Ink Licensing Deal for Glufast(R) Tablets II-112

AMRI Inaugurates New Research Unit in HyderabadII-113

Eisai Inks Co-Promotion Deal with Salix for COLAZAL(R) Capsules II-113

Kowa and Teva to Establish Joint Venture Generic Drug Firm in

Japan II-113

Nisshin Seifun Pulls Out of Joint Venture Nisshin Kyorin

Pharmaceutical II-114

Chugai and Teijin Sign Agreement for Co-Development of Anti-

Diabetic Drug II-114

MedImmune Inks Licensing Agreement with Novartis over Reverse

Genetic Technology II-114

EUSA Acquires Assets of Innocoll II-115

Noven Enters Supply and License Agreements with P&G

Pharmaceuticals II-115

Parion and Gilead Ink Deal to Develop Drug Candidates for

Pulmonary Disease II-116

Noven Pharmaceuticals Acquires JDS Pharmaceuticals II-116

HHS Places an Order with GSK for Bulk H5N1 Antigen II-117

Synthon Completes Laboratorios Rider Acquisition II-117

Targacept Forges Partnership with GSK II-118

Dong Wha Signs Alliance with P&G Pharma to Develop Treatment

Molecules for Osteoporosis II-118

Barr and Gedeon Richter Sign Pact over Generic Version of

LAMISIL(R) II-118

Santarus and Victory Pharma Enter Into Co-Promotion Agreement II-119

AMRI Enters into Collaboration for Research with Achaogen II-119

SCI Collaborates with High Q Foundation for Research on

Huntington’s Disease II-120

MonoSol Rx Signs License Agreement with Strativa Pharmaceuticals II-120

Eli Lilly to Launch Public-Private Partnership for Drug

Research in Tuberculosis II-120

Merck Serono and Bristol-Myers Squibb Ink Latin American

Distribution Deal II-121

Strides Arcolab to Take Over Bio-Fermentation Facility in Italy II-121

Amgen to Take Over Alantos Pharmaceuticals II-121

GlaxoSmithKline Establishes R&D Center in ChinaII-122

Wockhardt Acquires Negma Laboratories II-122

Eisai Inks Exclusive Agreement with Solstice over NeuroBloc(R) II-122

Ranbaxy to Acquire Be-Tabs Pharmaceuticals II-123

Pfizer Obtains Health Canada Approval for LIPITOR in Reducing

Myocardial Infarction II-123

GSK Allies with Wellcome to Develop Antibacterials for

Hospital-Contracted Infections II-124

Bristol-Myers and Pfizer Ink Development and

Commercialization Agreements II-124

Cytos Biotechnology Grants Novartis with Global License for

NicQb II-125

Swiss Federal Register Adds ACOMPLIA(R) to Reimbursement List II-125

Wockhardt to Introduce Syrio Pharma’s B-Lift Product Range in

India II-126

Eisai Acquires MorphotexII-126

Ranbaxy Obtains Approval for RAN(TM) Cefprozil Formulations in

Canada II-126

Roche Partners with Transgene to Focus on Therapeutic Vaccine

Program II-127

Cardinal Health Divests Pharmaceutical Technologies and

Services Segment to Blackstone Group II-127

Roche to Acquire BioVeris Corporation II-128

Eli Lilly Acquires Hypnion II-128

Roche Takes Over THP, Broadens Antibody Research Facility II-128

Oxford BioMedica Enters into Development Deal with Sanofi-

Aventis for TroVax(R) II-129

Iroko Pharmaceuticals Acquires Rights to Indocin(R) and

Aldomet(R) Products II-129

Asahi Kasei Inks Licensing Agreement with Eisai Korea over

Vasodilator Eril(R) II-129

Merck Obtains EU Approval for JANUVIA(TM) Type 2 Diabetes Drug II-130

Wockhardt Obtains FDA Approval for a Painkiller in the US II-130

Ortho-McNeil Obtains Pediatric Extension for LEVAQUIN(R) II-131

GlaxoSmithKline Obtains FDA Approval for Tykerb(R) II-131

Terapia Ranbaxy Secures Marketing Approvals for 20 New Products II-131

Shionogi to Develop and Market BioCryst’s peramivir in Japan II-131

Abbott and Eisai Amend Co-Promotion Agreement over HUMIRA(R) in

Korea and Taiwan II-132

Salix Acquires US Rights to Merck’s Two Oral Suspension Products II-132

Takeda Expands Collaboration with XOMA in Potential

Therapeutic Antibody Programs II-133

GSK Commences Phase III Clinical Trials of Tykerb(R), a Post-

Operative Lapatinib II-133

Roche Grants Glaxo with Exclusive Licensing Rights to its ‘

Orlistat’ Drug II-134

GSK and HGS Commence Phase III Trials of LymphoStat-B(R) in SLE II-134

GSK and Fabre-Kramer Ink Global Deal for Gepirone ER II-134

Ranbaxy Signs Agreement with Zenotech for Biosimilars’ Global

Launch II-135

Ranbaxy Inks Long-Term R&D Deal with GSK II-135

Amgen Inks Three-year Aranesp Supply Agreement with Fresenius II-136

AstraZeneca to Take Over Arrow Therapeutics II-136

Eli Lilly Acquires ICOS CorporationII-136

Pfizer Plans to Takeover BioRexis II-136

Solvay Inks Licensing Deal with Jazz Pharmaceuticals for LUVOX(R) II-137

Eisai’s'Pariet(R), 10mg Tablets’ Receive Clearance for New

Indication in Japan II-137

Eisai Receives EC Approval for Inovelon(R) II-137

Pfizer Receives Marketing Authorization for Sutent(R) in

European Union II-137

GlaxoSmithKline Obtains Approval to Market Wellbutrin XR(R) in

the Netherlands II-138

Forest Laboratories Acquires US Biopharmaceutical Company,

Cerexa II-138

Mylan Laboratories Acquires 51.5% in Matrix II-139

DUSA Enters into an Agreement with Daewoong Pharmaceutical II-139

Penwest and Endo Amend Existing Contract on Opana(R) ER

Collaboration II-139

Eli Lilly Licenses Glucokinase Activator Program from OSI

Pharmaceuticals II-140

Graceway Pharmaceuticals Acquires 3M Pharmaceuticals Business II-140

Ranbaxy Obtains FDA Approval for Atenolol Tablets II-140

Gilead Sciences Acquires Myogen II-141

Gilead Sciences Acquires Raylo Chemicals II-141

9. FDA APPROVALS FOR 2009, 2008 AND 2007 II-142

10. A REVIEW OF SELECT PRODUCT INTRODUCTIONS IN THE PHARMA INDUSTRY II-144

Amgen Receives Approval for Nplate(R) II-144

Takeda Wins FDA Marketing Approval for ULORIC II-144

Novartis and MMV Launch Coartem(R) Dispersible II-144

Ipsen and Medicis Receives FDA Approval for Dysport II-144

Centocor Receives FDA Approval for Simponi II-145

Wyeth Receives FDA Approval for PRISTIQ(TM) II-145

GSK Receives FDA Approval for Promacta(R) II-145

Cephalon Receives FDA Approval for TREANDA II-145

Adolor Receives FDA Approval For Entereg(R) II-145

Lundbeck Introduces Xenazine* (Tetrabenazine) Tablets II-146

Eisai US Receives FDA Approval for Banzel(TM) (Rufinamide) II-146

Progenics Receives FDA Approval for RELISTOR II-146

J&J Receives Approval for Anti-HIV Medication ‘Intelence’ II-146

Sandoz Launches Generic Fluoxetine Hydrochloride Capsules in US II-146

Sandoz Introduces Eplerenone Tablets II-147

Wockhardt Introduces Midazolam Injection in the US II-147

Dr. Reddy’s Announces Launch of Gener

To order this report:

FoodService Disposables

http://www.reportlinker.com/p0131234/FoodService-Disposables.html

More market research reports here!

CONTACT:

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker


Source: newswire



comments powered by Disqus